Research programme: controlled-release ophthalmic therapeutics - EyeGate Pharma

Drug Profile

Research programme: controlled-release ophthalmic therapeutics - EyeGate Pharma

Alternative Names: CMHA-S films - EyeGate Pharma; Controlled-release antibacterial ophthalmic therapeutics - EyeGate Pharma; EyeGate OBG; JDE 001; JDE 003; Ocular bandage gel - EyeGate Pharma; Recombinant hGH - EyeGate Pharma; Recombinant human growth hormone - EyeGate Pharma; Somatropin - EyeGate Pharma

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Jade Therapeutics
  • Developer EyeGate Pharma
  • Class Growth hormones
  • Mechanism of Action Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Corneal injuries; Infectious keratitis

Most Recent Events

  • 13 Sep 2016 Jade Therapeutics receives a second year of SBIR grant from the US Army Medical Research and Materiel Command for controlled-release opthalmic therapeutics development in corneal injuries
  • 01 Aug 2016 Preclinical development is ongoing in USA
  • 07 Mar 2016 Jade Therapeutics has been acquired by EyeGate Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top